|
Home | Medical-Newswire.Com:
|
(Medical-NewsWire.com, January 06, 2019 ) Sociable Pharma’s ‘Treatment Landscape’ contains evaluations of ongoing development activities within the Rheumatoid Arthritis (RA) market, analysis of current & potential future product positioning, and forecast approval dates (by quarter) for candidates in Phase II development, or higher -
- Executive Summary: Contains analysis of key market events that have occurred during the previous month and which have impacted Sociable Pharma’s view of the disease landscape
- Landscape Updates: ‘Order of Entry’ analysis, detailing timeline forecasts for each drug in Phase II development or higher; Timeline forecasts for each approved product’s lifecycle management initiatives; ‘Market Entry’ & ‘Direction of Travel’ positioning analysis for pipeline & currently approved therapies
- Pipeline Landscape: An overview of pipeline candidates, containing snapshots of current development status; Expected drug-specific events & milestones until YE 2019
- Approved Product Landscape: An overview of pipeline candidates, containing snapshots of current development status; Expected drug-specific events & milestones until YE 2019
Get Sample Copy of this Report@ https://www.orbisresearch.com/contacts/request-sample/2435849
Key Highlights:
- If the results of the Phase II MANTA safety trial are required by the FDA prior to filing for regulatory approval of filgotinib for RA, this could delay US approval by 2 years
- Given that the Phase II NCT03241108 trial is limited to 90 patients in the EU, it is likely that NovImmune will need to initiate a second Phase II trial with a larger number of patients, including US patients, prior to proceeding with a Phase III program for NI-0101 in RA
- The Phase II trial assessing the immunogenicity and safety of Zostavax in RA patients using abatacept, if positive, is likely to boost physician opinion of abatacept’s safety profile in RA, and reduce potential physician concerns that the use of abatacept may negatively impact the effectiveness of some immunizations, as suggested by its US FDA label.
Scope:
- The briefing is based on Sociable Pharma’s analysis of clinical trial data from company announcements (press releases, earnings calls) and clinical trial databases (clinicaltrials.gov)
- Sociable Pharma applies disease & drug specific assumptions in order to forecast US & EU approvals for drugs in Phase II development, or higher - these are outlined in the report Appendix
- Forecasts are presented in pipeline forecast figures & detailed tables
- ‘Market Entry’ & ‘Direction of Travel’ positioning analysis for pipeline & currently approved therapies is also provided.
Reasons to buy:
- Provides details on forecast US & EU approvals for pipeline drugs in Phase II development or higher
- Includes potential positioning strategies that companies may adopt for their novel assets once they are approved & launched in the market
- Reviews ongoing lifecycle management strategies for existing players in the market
- A detailed methodology allows you to understand the forecast assumptions made, enabling cross comparison with your own internal forecasts.
Make an Inquiry before Buying@ https://www.orbisresearch.com/contacts/enquiry-before-buying/2435849
Key Players:
• AbbVie
• Abivax
• Ablynx
• ACEA Biosciences
• Acerta Pharma
• Akari Therapeutics
• Akros Pharma
• Amgen
• Asana Biosciences
• Astellas
• AstraZeneca
• Bayer
• Biocad
• Bird Rock Bio
• BMS
• Boehringer Ingelheim
• Can-Fite Biopharma
• Celgene
• Chemo-Centryx
• Cyclacel
• Daichii Sankyo
• Eddingpharm
• Eisai
• Galapagos
• Genentech
• Gilead
• GSK
• Hanmi
• Hutchison Medi Pharma
• Innate Pharma
• Innocare Pharma
• Istesso
• Janssen
• Japan Tobacco
• Jiangsu HengRui
• Lilly
• Lupin
• MacroGenics
• MedImmune
• Merck KGaA
• Mesoblast
• Momenta
• MorphoSys
• Morphotek
• MSD
• Nektar Therapeutics
• Novartis
• NovImmune
• Noxopharm
• Nuevolution
• Oscotec
• OSE Immuno Therapeutics
• Pfizer
• Philogen
• Principia Biopharma
• Protalex
• Reata Pharmaceuticals
• Regen BioPharma
• Regeneron
• Rigel Pharmaceuticals
• Roche
• Rottapharm Biotech
• R-Pharm
• Sanofi
• Sareum
• Swedish Orphan Biovitrum
• Taiho
• Taisho
• Takeda
• TiGenix
• UCB
• Valeant
• Viela Bio
• Vitaeris
• WuXi
• Xencor
Get More Information about this Report@ https://www.orbisresearch.com/reports/index/competitor-landscape-rheumatoid-arthritis
About Us:
Orbis Research (orbisresearch.com) is a single point aid for all your market research requirements. We have vast database of reports from the leading publishers and authors across the globe. We specialize in delivering customized reports as per the requirements of our clients. We have complete information about our publishers and hence are sure about the accuracy of the industries and verticals of their specialization. This helps our clients to map their needs and we produce the perfect required market research study for our clients.
Orbis Research
Hector Costello
+1 (214) 884-6817
sales@orbisresearch.com
Source: EmailWire.Com 
Source: EmailWire.com
|
|
|
|
